Association between low-dose pulsed intravenous cyclophosphamide therapy and amenorrhea in patients with systemic lupus erythematosus: A case-control study

Table 1 Characteristics of study subjects with SLE (IVCY group and steroid group)

	IVCY group	Steroid group	p ^†
	n = 29	n = 33
Age (years)	31 (18-45)	30 (19-45)	0.16
Subjects < 40 years old	21 (72%)	30 (91%)
Subjects ≥ 40 years old	8 (28%)	3 (9%)	0.09
Duration of SLE (months)	7 (1-153)	2 (1-241)	0.05
SLE manifestation
Nephritis	15 (52%)	13 (39%)	0.44
CNS lupus	7 (24%)	1 (3%)	0.02
Vasculitis	5 (17%)	1 (3%)	0.09
Cytopenia	7 (24%)	10 (30%)	0.78
SLEDAI-2K	16 (2-31)	10 (3-18)	0.0004
Max. dose of prednisolone (mg)	50 (14-125)	45 (40-100)	0.79
Glucocorticoid pulse therapy	6 (20%)	6 (18%)	1.00
Total dose of cyclophosphamide (mg)	1000 (500-6500)
Total number of IVCY (time)	2 (1-13)

*Except where indicated otherwise, values of continuous data are the median (range).
^† p values were determined by Fisher's exact test or Mann-Whitney U test.
IVCY intravenous cyclophosphamide, SLE systemic lupus erythematosus, CNS central nervous system, SLEDAI-2K systemic lupus erythematosus disease activity index 2000.

ISSN: 1472-6874